01—Abstract
Summary
Summary of the 8-K filed April 22, 2025. Cited figures are marked; the original filing is the authoritative source.
Danaher reported first-quarter 2025 results for the period ended March 28, 2025, with GAAP sales of $5.74 billiona, down 1.0% year over year.
Non-GAAP core sales were flat, which management described as ahead of its expectations. GAAP net earnings were $954 millionb, or $1.32 per diluted share, versus $1.45 a year earlier. Adjusted diluted EPS was $1.88, down from $1.92.
The decline in GAAP earnings was driven by higher amortization of acquisition-related intangibles, a larger fair value loss on investments, and lower interest income. Operating cash flow was $1.30 billionc and free cash flow was $1.06 billion (the press release rounds these to $1.3 billion and $1.1 billion). Segment performance was uneven.
Biotechnology was the clear standout, with core sales up 7%d, which management attributed to continued bioprocessing momentum. Life Sciences core sales fell 4%, and Diagnostics core sales declined 1.5%, though molecular diagnostics respiratory demand was better than expected. Management said the macro backdrop has become more dynamic, citing tariffs and related trade actions as a forward-looking risk.
For guidance, management expects second-quarter core revenue to grow at a low-single-digit rate year over year. Full-year 2025 core revenue growth of approximately 3% is unchanged.
Danaher is initiating full-year adjusted diluted EPS guidance of $7.60 to $7.75. The company does not provide GAAP EPS guidance because of the difficulty of forecasting investment gains and losses and discrete tax items.
02—Key points
Key Highlights
- GAAP sales of $5.74B, down 1.0% YoY; non-GAAP core sales were flat, with acquisitions/divestitures a 0.5-point headwind and currency a 1.5-point tailwind.
- GAAP diluted EPS of $1.32 (vs. $1.45) and adjusted diluted EPS of $1.88 (vs. $1.92). Amortization of acquisition intangibles ($0.57/share) and investment losses ($0.12/share) were the main adjustments.
- Biotechnology core sales rose 7%, led by bioprocessing, while Life Sciences (-4%) and Diagnostics (-1.5%) declined on a core basis.
- Operating cash flow was $1.30B (vs. $1.74B) and free cash flow was $1.06B (vs. $1.45B). Financing outflows were $1.26B, versus $133M a year earlier.
- Interest income fell to $6M from $60M, and interest expense rose to $72M from $65M, reflecting a shift in the company's cash and debt position.
- Q2 2025 core revenue guidance is low-single-digit growth. Full-year core growth of ~3% is unchanged.
- Initial FY2025 adjusted diluted EPS guidance is $7.60 to $7.75, with no GAAP EPS guidance provided.
03—Questions
Frequently Asked Questions
Did Danaher meet expectations in Q1 2025?
Management said revenue, earnings, and cash flow exceeded its expectations. Core sales were flat, and adjusted EPS of $1.88 was below the prior-year $1.92, though the filing does not state consensus estimates. Strength in Biotechnology and better-than-expected respiratory demand in molecular diagnostics offset weakness in Life Sciences.
Why did GAAP earnings decline more than adjusted earnings?
GAAP diluted EPS fell to $1.32 from $1.45, about 9%, while adjusted EPS fell to $1.88 from $1.92, about 2%. The gap reflects larger non-GAAP adjustments this quarter, mainly a $0.12 per share fair value loss on investments (vs. $0.05 a year earlier) and a $0.02 impairment charge, along with lower interest income. Amortization of acquisition intangibles was a $0.57 adjustment in both periods' calculations and is excluded from adjusted EPS.
What is the outlook for the rest of 2025?
Danaher expects Q2 core revenue to grow at a low-single-digit rate and full-year core revenue to grow about 3%, unchanged from prior guidance. It is initiating full-year adjusted diluted EPS guidance of $7.60 to $7.75. The company cited a more dynamic macro environment, including tariffs, as a risk to the outlook.
Which business segments are driving growth and which are lagging?
Biotechnology is the growth engine, with core sales up 7% on bioprocessing demand. Life Sciences core sales fell 4%, and Diagnostics fell 1.5%. Diagnostics was supported by respiratory testing demand, which exceeded expectations.
How strong is Danaher's cash generation and balance sheet activity?
Free cash flow was $1.06B, down from $1.45B, as operating cash flow fell to $1.30B from $1.74B. Financing outflows of $1.26B (vs. $133M) suggest significant debt repayment or capital returns, though the filing does not itemize them. Management emphasized the strength of the balance sheet as a differentiator.
04—Continue